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The study aimed to establish the common reasons for non-adherence to drug 
treatment among breast cancer patients at the Obafemi Awolowo University 
Teaching Hospitals Complex, Ile-Ife, Nigeria over a ten-year period (Jan 1993 - 
Dec 2002). Patients’ adherence and reasons for non-adherence to chemotherapy 
were evaluated using descriptive statistics. Two hundred and twenty-five breast 
cancer patients including 199 females and 6 males with breast cancer were 
recruited. 12(5.3%) patients had Stage I disease while 126 (56%) were in stage 
IV. The non-adherence rate was 80.9% and 111(73%) of the non-adherent 
patients were eventually not seen again.  Of the one hundred and one patients 
who gave reasons for non-adherence, 45% complained of financial difficulties; 
18% thought they were well enough; 15% were fearful of subsequent operation 
and 11% were unable to further bear the drug side effects. In conclusion, the 
study demonstrated poor economic status of the patients as one of the major 
reasons for non-adherence to cancer chemotherapy in Nigeria. Government 
subsidy of breast cancer treatment, improved health education and advocacy 
complemented by home visiting to encourage hospital attendance would be 
required for better adherence to chemotherapy. 
 




The burden of breast cancer in developing 
countries is enormous [1]. A twofold increase 
has been reported in the incidence in Ibadan, 
Nigeria and in Kampala, Uganda in the recent 
past [2,3]. A more aggressive disease course 
has also been noted as reported from Jos in 
northern Nigeria where most patients 
presented with high grade invasive ductal 
carcinoma which were oestrogen receptor 
(ER) and progesterone receptor (PR) negative 
but p53 positive [4]. The patients also 
commonly present late, with advanced disease 
and are frequently lost to follow up early in 
management with poor overall survival rate in 
different centres across Africa [1,5,9]. 
The major role of chemotherapy in the 
management of breast cancer and its efficacy 
in prolonging survival has been well 
documented [10-13]. The beneficial effects of 
chemotherapeutic agents can only be realised 
if patients comply with their use. Compared 
with the developed countries, patients’ 
compliance with chemotherapy in developing 
countries has been shown to be poorer [14-17]. 
More recently, the more authority-
laden term “compliance” is largely being 
replaced with the term “adherence” in the 
literature due to increase in patient autonomy. 
Many health care providers prefer the word 
“adherence”, because "compliance" suggests 
that the patient is passively following the 
doctor's orders and that the treatment plan is 
not based on an established therapeutic 
agreement between the patient and the 
physician The most commonly cited definition 
of adherence is ‘the extent to which a person’s 
behaviour coincides with medical or health 
advice’. [18,19] The aim of this study was to 
determine the level of adherence to 
chemotherapy as well as factors that may 
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influence this among breast cancer patients in 
our environment. 
 
Materials and Methods 
 
A review of the clinical records of 
histologically proven cases of breast cancer 
seen over a ten year period of January 1993 
through December 2002 at the Ife Hospital 
Unit of the Obafemi Awolowo University 
Teaching Hospitals Complex (OAUTHC), Ile-
Ife, South-West Nigeria was carried out. 
Those whose hospital records were incomplete 
were excluded.  Demographic and clinical 
information including treatment records were 
studied. Chemotherapeutic agents received, 
the numbers of courses, patient’s adherence as 
well as details of non-adherence were further 
studied.  
 A patient was considered to be non-
adherent if they did not present for two 
consecutive doses of chemotherapy. Patients 
who had dose reduction and/ or omission due 
to inadequate haematological profile or poor 
clinical condition were not included as 
defaulters. The patients who missed their 
medications due to no fault of theirs either 
because of unplanned public holidays or other 
reasons beyond their control were excluded 





There were 225 cases of breast cancer seen 
during the study period. Majority (97.3%) 
were females and 6 were males. The ages 
ranged from 26 to 86 years with a mean of 48 
(SD: 12.3) years. More than one quarter of the 
patients were under 40years of age, with 
69(30.6%) being 40-49years old, and 
13(5.8%) 70years and above. There were more 
lesions on the right (47.1%) than the left 
(44.1%). Twenty patients (8.9%) had bilateral 
breast involvement at presentation. Using the 
American Joint Committee on Cancer (AJCC) 
staging system, 12 (5.3%) patients presented 
in Stage I, 28 (12.4%) in stage II, 59 (26.2%) 
in stage III and 126 (56%) in stage IV (Table 
I). Presentation at advanced stage was 
recorded for all age groups. 
Twenty-six patients who presented in 
very poor clinical condition died before 
chemotherapy could be instituted while 
another eleven refused chemotherapy even 
after adequate counselling. On the whole, 188 
of the 225 patients had chemotherapy. Of 
these, 59 (31.4%) had neo-adjuvant 
chemotherapy alone, 81 (43.1%) had adjuvant 
chemotherapy while 48 (25.5%) had both neo-
adjuvant and adjuvant chemotherapy. CMF 
combination chemotherapy 
(Cyclophosphamide, Methotrexate and 5-
Fluorouracil) was used in 149 patients, while 
CAF (Cyclophosphamide, Adriamycin and 5-
Fluorouracil) was used in combination for 21 
patients. CMF with Vincristine (CMFV) was 
used in 12 patients. 92 (48.9%) patients had 
Tamoxifen prescribed along with their 
chemotherapy. (Table II) 
The non-adherence rate was 80.9% 
(152 of 188) and a pattern of non-adherence 
was seen across all age groups, chemotherapy 
combinations and disease stage. Forty (21.3%) 
patients defaulted before the end of the first 
course while 95 (50.5%) patients defaulted 
within the first three courses of chemotherapy. 
Also, we found that at one year after 
defaulting, 111(73%) of these patients had not 
returned for further treatment and many were 
subsequently lost to follow up. Only 7 patients 
came back to continue treatment within a 
month of defaulting. 
 The reasons for non-adherence were 
available in only 101 cases. Of these, 45 
(45%) were noted to have defaulted due to 
financial constraints, 18 (18%) patients 
because they felt well; 15 (15%) because of 
fear of subsequent operation; 11 (11%) did so 
because of unbearable drug side effects, while 
19(19%) patients defaulted for various other 
reasons. 
The group of patients (N= 18) who 
were non-adherent because they felt well were 
aged between 30-45years and 16 of them had 
stage I and II diseases. Nine had neo-adjuvant 
chemotherapy with very good response and 
indeed 5 out of them had a dramatic response 
with non-palpable tumours after the first 
course of chemotherapy. The remaining 9 had 
mastectomy but defaulted before, during or 
after the first course of adjuvant 
chemotherapy. Twelve patients of this group 
were lost to follow up while 6 re-presented 
again with stage IV disease. 
 In the final analysis, 51patients 
(22.6%) died during the course of treatment, 
22 (9.8%) patients were referred for 
radiotherapy, 15 (6.7%) re-presented with 
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recurrence after initial treatment, 5 (2.3%) 
were adjudged to be cured of the disease 
(having attended follow-up clinic for over 
5years without any recurrence), while 132 
(58.7%) patients were lost to follow-up.
 
Table 1: Age and Stage at Presentation of Women with Breast Cancer in Ile-Ife, Nigeria. 
Age       Stage at Presentation 
(Yr)    N  StageI   StageII    StageIII      StageIV 
<30    6     2       -    1         3  
30-39    50     1       6  14       29 
40-49    69     4     11  14       40 
50-59    49     4       7  15       23  
60-69    38     1       3    8       26 
70-79    11     -       1    6         4 
≥80    2     -       -    1         1 
 
Table 2: Use of Chemotherapy in Women with Breast Cancer in Ile-Ife, Nigeria. 
Drugs Used   No (%)  Neo-Adjuvant       Adjuvant 
CMF    149 (79.3%)  112   52 
CAF    21 (11.2%)    9   12 
CAMF    12 (6.4%)  2   10 
CMFV    6 (3.2%)                 1   5 
Tamoxifen   92 (48.9%)  70   42 
 
Table 3: Reasons for Non-Adherence with Chemotherapy Schedule 
 
                               Reason                 No   Percentage 
                               Financial Difficulty  45   45% 
                               Feels Well   18   18% 
                               Fear of Operation  15   15% 
                               Drug Side Effects  11   11% 
                               Others    19   19% 




The findings in this study suggesting a high 
incidence of breast cancer in young women 
with more than one quarter of the patients 
being below 40years of age has been the 
experience of others in previous studies across 
Nigeria [7,8,20]. The reason why breast cancer 
tends to occur in younger age groups in 
Africans is not yet known. It may however be 
related to the young population of most of the 
African countries just like other developing 
countries. 
The problem of late presentation in the 
hospital, a common phenomenon among 
patients in developing countries, was also 
observed in this study. One hundred and 
twenty-six patients (56%) presented with stage 
IV disease. Similar findings have also been 
reported in many studies on breast cancer 
across Nigeria and in other developing 
countries [7-9,21,22]. This may be due to poor 
awareness of the disease among the population 
as well as low level of organised public 
enlightenment and screening programmes in 
most developing countries. Okobia et al 
reported a poor knowledge of breast cancer 
among rural dwelling women in Nigeria with 
only a minority practising breast self 
examination and clinical breast examination 
[20]. A study in South Africa found that 77% 
of black women presented with Stages III and 
IV disease while only a few who reportedly 
practised self breast examination presented 
with stage I disease [23]. 
In view of the late stages of 
presentation, chemotherapy played a major 
role in the management of the patients. In this 
study more than 83% of the patients had 
chemotherapy as neo-adjuvant or adjuvant 
treatment or a combination of both. 81 patients 
had neo-adjuvant chemotherapy to downstage 
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the tumour preparatory for surgery while 130 
patients had adjuvant chemotherapy. This is 
largely due to the fact that a large number of 
the patients presented late thus precluding 
initial surgery. Combination chemotherapy 
was used in all the patients. The combination 
of Cyclophosphamide, Methotrexate and 5-
Fluorouracil (CMF) was used in most of the 
patients in this study. Anthracycline-based 
combinations, which are common in 
developed countries, were used in only 11% of 
the patients in this study largely due to its high 
cost. Similarly patients were not placed on 
newer chemotherapeutic agents such as the 
Taxanes as they were largely unavailable and 
unaffordable to most of our patients. 
Since there is no health welfare 
scheme in place in Nigeria during the period 
of the study, the burden of procuring 
expensive chemotherapeutic agents was borne 
by the patients and their relations. Significant 
proportion of the patients being agrarian and 
generally poor, could not afford the estimated 
average cost of US$100 for procuring a course 
of CMF chemotherapy. This probably affected 
patients’ adherence to the chemotherapy 
schedule in most instances. Indeed 45% of 
patients who gave reasons for non-adherence 
to chemotherapy cited financial constraint as 
the problem. In the experience of the authors, 
many of the patients in the environment are 
unable to procure more than the first course of 
chemotherapy and are usually not able to 
continue with the schedule. Perhaps if cancer 
treatment were to be subsidized again by the 
government (as was the case in the early 1980s 
in our part of the country) perhaps there would 
be significant improvement in the rate of non-
adherence. 
In a study of patients adherence to 
chemotherapy for breast cancer carried out at 
Sussex, United Kingdom, 55% of patients 
receiving chemotherapy were noted not to 
have adhered to medications either 
unintentionally (due largely to forgetfulness) 
or intentionally (due to drug side effects and 
difficulty swallowing tablets) [24]. Drug side 
effects have also been given as reason for non-
adherence among women taking Tamoxifen 
[25,26]. In the current series, 11 patients 
(5.8%) reported intentional non-adherence 
because of drug side effects. Some of these 
were young women who had severe alopecia 
and skin hyperpigmentation which were 
cosmetically unacceptable. Two of them had 
recurrent nausea and vomiting that 
necessitated admission for rehydration and 
they subsequently defaulted. 
It is of interest that 15 patients 
defaulted after counselling for mastectomy. In 
Africa, many women find it difficult to accept 
the option of mastectomy [27]. A study in 
Egypt observed that most of the women were 
primarily concerned with keeping their breasts 
regardless of the disease stage [28].  It is 
possible that the relatively young age of many 
of the women in this study, lack of 
understanding by their spouses, the general 
fear of surgery and anaesthesia as well as the 
relatively low rate of breast reconstruction 
surgeries were responsible for not readily 
consenting to mastectomy. Furthermore 
because most of the patients present with 
advanced disease, the option of breast 
conserving surgeries is not usually available 
for them. 
            It is also worthy of note that the group 
of 18 patients that defaulted for reason of 
being better were young adults with operable 
disease stages. One half of them were on neo-
adjuvant chemotherapy with significant effects 
including complete regression in five patients. 
The paradox of wellness and non-adherence is 
a difficult problem, as these patients would 
probably have benefited more from 
chemotherapy use. It is possible that religious 
belief in faith healing that is common in the 
environment and the initial tumour 
disappearance led to default based on bad 
advice.  
The clinic attendance by the patients 
was also a problem. More than one-half (132, 
representing 58.7%) of the patients were lost 
to follow-up at different points in the course of 
their treatment. This observation is similar to 
findings in many studies from developing 
countries [29-30].  Problems confronting the 
patients ranging from financial difficulties to 
the prolonged denial of the illness as well as 
the strong superstitious belief in the use of 
traditional and or spiritual healing approaches 
may contribute to this. The poor follow-up 
made it difficult to assess the efficacy of 
chemotherapy as well as the final outcome in 
many of the patients. Health education and 
advocacy as well as home visiting and tracing 
of breast cancer patients may reduce this 
problem. 
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Conclusion 
 
This study has, in highlighting the severe 
burden of breast cancer in Nigeria 
demonstrated poor economic status of the 
patients as one of the major reasons for non-
adherence to cancer chemotherapy. One way 
perhaps of encouraging patients to present and 
adhere to chemotherapy treatment is to 
introduce highly subsidized breast cancer 
treatment in government hospitals. Health 
education and advocacy complemented by 
home visiting to encourage hospital attendance 
may be required to improve the rate of 
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